Should cytomegalovirus (CMV) retinitis be screened for before initiating antiretroviral therapy (ART) in an adult with a CD4 count of 6 cells/µL?

CMV Retinitis Screening Before ART Initiation

CMV retinitis does not need to be formally "ruled out" before starting antiretroviral therapy in patients with CD4 counts <50 cells/µL, but a dilated funduscopic examination should be performed to detect existing disease, as ART should be initiated promptly regardless of CMV retinitis presence.

Screening Recommendations for High-Risk Patients

For patients with CD4 counts <50 cells/µL:

• Regular funduscopic examinations by an ophthalmologist are recommended by certain specialists, though this is a lower-strength recommendation (CIII) 1
• Patients should be educated to self-monitor for visual symptoms including floaters and changes in visual acuity by reading newsprint 1
• The primary method for preventing severe CMV disease is recognizing early manifestations, not delaying ART 1

ART Should Not Be Delayed

The evidence strongly supports initiating ART without delay, even in the presence of active CMV retinitis:

• No data demonstrate that starting ART in treatment-naïve patients with CMV retinitis has adverse effects on retinitis, gastrointestinal disease, or pneumonitis 1
• Appropriate ART should be administered to those with acute CMV retinitis (BIII recommendation) 1
• ART can control CMV retinitis without anti-CMV therapy in patients who experience immune recovery, though this takes 3-6 months 1

Clinical Context: The HAART Era Reality

CMV retinitis presentation has changed significantly since HAART became available:

• Most patients (63.5%) with newly diagnosed CMV retinitis are already receiving HAART at diagnosis, with only 17.5% being HAART-naïve 2
• CMV retinitis can occur even in patients with CD4 counts >100 cells/µL after starting HAART, particularly in those who had very low CD4 counts (≤85 cells/µL) before therapy initiation 3
• The early immunological effects of HAART may not provide sufficient protection to prevent CMV retinitis in patients with very low baseline CD4 counts 3

Risk Stratification

Highest risk patients who warrant closer ophthalmologic surveillance:

• CD4 count <50 cells/µL at any time 1, 4
• Positive CMV PCR at therapy initiation (38% 12-month event rate vs 2% in CMV PCR-negative patients) 4
• Higher CMV viral loads (mean 3700 vs 384 copies/ml in those who develop retinitis) 4

Important Caveats

Key clinical pitfalls to avoid:

• CMV retinitis can be asymptomatic, particularly in HAART-experienced patients with treatment failure 2
• Immune reconstitution inflammatory syndrome (IRIS) can unmask or paradoxically worsen CMV retinitis after ART initiation 5
• For CMV neurologic disease specifically, a brief delay in ART initiation until clinical improvement might be prudent due to potential IRIS-related morbidity (CIII), but this does NOT apply to retinitis 1
• Inflammation recurrence is significantly lower in ART-treated compared to non-ART-treated patients (10% vs 33%) 6

Practical Algorithm

For a patient with CD4 count of 6 cells/µL:

1. Perform dilated funduscopic examination if ophthalmology is readily available, but do not delay ART initiation for this 1

2. Initiate ART immediately regardless of CMV retinitis presence or absence 1

3. If CMV retinitis is detected: Start concurrent systemic anti-CMV therapy (valganciclovir) for 3-6 months until immune recovery occurs, as anti-CMV therapy decreases mortality in patients with CMV retinitis and immune compromise 1

4. If no retinitis detected: Educate patient on symptoms and arrange ophthalmology follow-up within 2-4 weeks, as clinical immunorestoration to CMV takes 3-8 months after HAART initiation 7